リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Platelet Transfusion Refractoriness in Single-Unit Cord Blood Transplantation For Adults: Risk Factors and Clinical Outcomes」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Platelet Transfusion Refractoriness in Single-Unit Cord Blood Transplantation For Adults: Risk Factors and Clinical Outcomes

田上, 晋 東京慈恵会医科大学 DOI:info:doi/10.1016/j.bbmt.2018.05.006

2020.10.15

概要

Platelet transfusion refractoriness (PTR) is frequently observed after allogeneic hematopoietic cell transplan- tation (HCT). However, the incidence of and risk factors for PTR, and impact of PTR on transplant outcomes after cord blood transplantation (CBT) have not been fully investigated. We retrospectively analyzed 185 adult patients who received single-unit CBT in our institute. The mean 16-hour corrected count increment (CCI) for the 5840 platelet transfusions was 3.68 × 109/L. Among them, 3196 transfusions (54.7%) were associated with a PTR with 16-hour-CCI <4.5 × 109/L. Results of multivariate analysis indicated that the following factors were significantly associated with decreased platelet transfusion responses: female sex with pregnancy history, male sex, the presence of HLA class I antibody, lower cord blood total nucleated cell dose, lower cord blood CD34+ cell dose, 3 locus HLA disparities, body temperature ≥38°C, C-reactive protein ≥10 mg/dL, cytomega- lovirus reactivation, use of foscarnet, and use of liposomal amphotericin B. By contrast, graft-versus-host disease prophylaxis including methotrexate, ABO minor mismatch, use of ganciclovir, and use of linezolid were sig- nificantly associated with better platelet transfusion responses. PTR had a significant effect on poor neutrophil and platelet recovery, and overall mortality after CBT. These data suggest that early phase PTR may be pre- dictive of engraftment and mortality after single-unit CBT for adults.

論文の公開元へ

関連論文

関連論文をもっと見る

参考文献

1. Schiffer CA, Bohlke K, Delaney M, et al. Platelet transfusion for patients with cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2018;36(3):283-299.

2. Christou G, Iyengar A, Shorr R, et al. Optimal transfusion practices after allogeneic hematopoietic cell transplantation: a systematic scoping review of evidence from randomized controlled trials. Transfusion. 2016;56(10):2607-2614.

3. Hogge DE, McConnell M, Jacobson C, Sutherland HJ, Benny WB, Massing BG. Platelet refractoriness and alloimmunization in pediatric oncology and bone marrow transplant patients. Transfusion. 1995;35(8):645- 652.

4. Balduini CL, Salvaneschi L, Klersy C, et al. Factors influencing post-transfusional platelet increment in pediatric patients given hematopoietic stem cell transplantation. Leukemia. 2001;15(12):1885- 1891.

5. Klumpp TR, Herman JH, Innis S, et al. Factors associated with response to platelet transfusion following hematopoietic stem cell transplantation. Bone Marrow Transplant. 1996;17(6):1035-1041.

6. Ishida A, Handa M, Wakui M, Okamoto S, Kamakura M, Ikeda Y. Clinical factors influencing posttransfusion platelet increment in patients undergoing hematopoietic progenitor cell transplantation–a prospective analysis. Transfusion. 1998;38(9):839-847.

7. Toor AA, Choo SY, Little JA. Bleeding risk and platelet transfusion refractoriness in patients with acute myelogenous leukemia who undergo autologous stem cell transplantation. Bone Marrow Transplant. 2000;26(3):315-320.

8. Kerkhoffs JL, Eikenboom JC, van de Watering LM, van Wordragen-Vlaswinkel RJ, Wijermans PW, Brand A. The clinical impact of platelet refractoriness: correlation with bleeding and survival. Transfusion. 2008;48(9):1959-1965.

9. Li G, Liu F, Mao X, Hu L. The investigation of platelet transfusion refractory in 69 malignant patients undergoing hematopoietic stem cell transplantation. Transfus Apher Sci. 2011;45(1):21-24.

10. Solves P, Sanz J, Freiria C, et al. Factors influencing platelet transfusion refractoriness in patients undergoing allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2018;97(1):161-167.

11. Bishop JF, Matthews JP, McGrath K, Yuen K, Wolf MM, Szer J. Factors influencing 20-hour increments after platelet transfusion. Transfusion. 1991;31(5):392-396.

12. Scott A, Baidya S, Butler J, Morris K, Thornton A, Kennedy GA. Pretransplant platelet transfusion refractoriness is not associated with platelet nonengraftment in T-replete hematopoietic progenitor cell transplantation for hematologic malignancies. Transfusion. 2016;56(1):164-169.

13. Fu Q, Xu L, Zhang X, et al. Platelet transfusion refractoriness after T-cell-replete haploidentical transplantation is associated with inferior clinical outcomes. Sci China Life Sci. 2018;61(5):569-577

14. Milano F, Gooley T, Wood B, et al. Cord-blood transplantation in patients with minimal residual disease. N Engl J Med. 2016;375(10):944-953.

15. Terakura S, Atsuta Y, Tsukada N, et al. Comparison of outcomes of 8/8 and 7/8 allele-matched unrelated bone marrow transplantation and single-unit cord blood transplantation in adults with acute leukemia. Biol Blood Marrow Transplant. 2016;22(2):330-338.

16. Takahashi S, Iseki T, Ooi J, et al. Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood. 2004;104(12):3813-3820.

17. Konuma T, Tsukada N, Kanda J, et al. Comparison of transplant outcomes from matched sibling bone marrow or peripheral blood stem cell and unrelated cord blood in patients 50 years or older. Am J Hematol. 2016;91(5):E284-E292.

18. Pei R, Wang G, Tarsitani C, et al. Simultaneous HLA Class I and Class II antibodies screening with flow cytometry. Hum Immunol. 1998; 59(5):313-322.

19. Hod E, Schwartz J. Platelet transfusion refractoriness. Br J Haematol. 2008;142(3):348-360.

20. Stanworth SJ, Navarrete C, Estcourt L, Marsh J. Platelet refractoriness– practical approaches and ongoing dilemmas in patient management. Br J Haematol. 2015;171(3):297-305.

21. Giralt S, Ballen K, Rizzo D, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2009;15(3):367-369.

22. Armand P, Kim HT, Logan BR, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014;123(23):3664-3671.

23. Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48(3):452-458.

24. Konuma T, Ooi J, Uchida N, et al. Granulocyte colony-stimulating factor combined regimen in cord blood transplantation for acute myeloid leukemia: a nationwide retrospective analysis in Japan. Haematologica. 2014;99(12):e264-e268.

25. Konuma T, Kato S, Oiwa-Monna M, Tojo A, Takahashi S. Single-unit cord blood transplant for acute lymphoblastic leukemia and lymphoma using an intensified conditioning regimen of total body irradiation, high-dose cytarabine and cyclophosphamide. Leuk Lymphoma. 2015;56(4):1148- 1150.

26. Patel KJ, Rice RD, Hawke R, et al. Pre-engraftment syndrome after double-unit cord blood transplantation: a distinct syndrome not associated with acute graft-versus-host disease. Biol Blood Marrow Transplant. 2010;16(3):435-440.

27. Konuma T, Kohara C, Watanabe E, et al. Cytokine profiles of pre- engraftment syndrome after single-unit cord blood transplantation for adult patients. Biol Blood Marrow Transplant. 2017;23(11):1932-1938.

28. Narimatsu H, Terakura S, Matsuo K, et al. Short-term methotrexate could reduce early immune reactions and improve outcomes in umbilical cord blood transplantation for adults. Bone Marrow Transplant. 2007;39(1):31-39.

29. Iguchi A, Terashita Y, Sugiyama M, et al. Graft-versus-host disease (GVHD) prophylaxis by using methotrexate decreases pre-engraftment syndrome and severe acute GVHD, and accelerates engraftment after cord blood transplantation. Pediatr Transplant. 2016;20(1):114-119.

30. Terakura S, Wake A, Inamoto Y, et al. Exploratory research for optimal GvHD prophylaxis after single unit CBT in adults: short-term methotrexate reduced the incidence of severe GvHD more than mycophenolate mofetil. Bone Marrow Transplant. 2017;52(3):423-430.

31. Böck M, Muggenthaler KH, Schmidt U, Heim MU. Influence of antibiotics on posttransfusion platelet increment. Transfusion. 1996;36(11–12):952- 954.

32. Slichter SJ, Davis K, Enright H, et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood. 2005;105(10):4106-4114.

33. Comont T, Tavitian S, Bardiaux L, et al. Platelet transfusion refractoriness in patients with acute myeloid leukemia treated by intensive chemotherapy. Leuk Res. 2017;61:62-67.

34. Gluckman E, Rocha V, Arcese W, et al. Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice. Exp Hematol. 2004;32(4):397-407.

35. Konuma T, Kato S, Oiwa-Monna M, et al. Cryopreserved CD34+ Cell Dose, but not total nucleated cell dose, influences hematopoietic recovery and extensive chronic graft-versus-host disease after single-unit cord blood transplantation in adult patients. Biol Blood Marrow Transplant. 2017;23(7):1142-1150.

36. Christou G, Kekre N, Petrcich W, et al. Impact of platelet transfusion on toxicity and mortality after hematopoietic progenitor cell transplantation. Transfusion. 2015;55(2):253-258.

37. Kim DH, Sohn SK, Jeon SB, et al. Prognostic significance of platelet recovery pattern after allogeneic HLA-identical sibling transplantation and its association with severe acute GVHD. Bone Marrow Transplant. 2006;37(1):101-108.

38. Ramírez P, Brunstein CG, Miller B, Defor T, Weisdorf D. Delayed platelet recovery after allogeneic transplantation: a predictor of increased treatment-related mortality and poorer survival. Bone Marrow Transplant. 2011;46(7):981-986.

39. Akahoshi Y, Kimura SI, Gomyo A, et al. Delayed platelet recovery after allogeneic hematopoietic stem cell transplantation: association with chronic graft-versus-host disease and survival outcome. Hematol Oncol. 2017;36(1):276-284.

40. Labrador J, Lopez-Anglada L, Perez-Lopez E, et al. Analysis of incidence, risk factors and clinical outcome of thromboembolic and bleeding events in 431 allogeneic hematopoietic stem cell transplantation recipients. Haematologica. 2013;98(3):437-443.

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る